DESIPRAMINE HYDROCHLORIDE - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for desipramine hydrochloride and what is the scope of patent protection?
Desipramine hydrochloride
is the generic ingredient in three branded drugs marketed by Sanofi Aventis Us, Actavis Totowa, Alembic, Amneal Pharms Co, Ani Pharms, Chartwell Rx, Heritage Pharms, Novast Labs, Usl Pharma, and Validus Pharms, and is included in eighteen NDAs. Additional information is available in the individual branded drug profile pages.There are seven drug master file entries for desipramine hydrochloride. Ten suppliers are listed for this compound.
Summary for DESIPRAMINE HYDROCHLORIDE
US Patents: | 0 |
Tradenames: | 3 |
Applicants: | 10 |
NDAs: | 18 |
Drug Master File Entries: | 7 |
Finished Product Suppliers / Packagers: | 10 |
Raw Ingredient (Bulk) Api Vendors: | 89 |
Clinical Trials: | 61 |
Patent Applications: | 2,258 |
What excipients (inactive ingredients) are in DESIPRAMINE HYDROCHLORIDE? | DESIPRAMINE HYDROCHLORIDE excipients list |
DailyMed Link: | DESIPRAMINE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for DESIPRAMINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University College, London | Phase 3 |
London North West Healthcare NHS Trust | Phase 3 |
University Hospital Plymouth NHS Trust | Phase 3 |
Pharmacology for DESIPRAMINE HYDROCHLORIDE
Drug Class | Tricyclic Antidepressant |
Medical Subject Heading (MeSH) Categories for DESIPRAMINE HYDROCHLORIDE
Anatomical Therapeutic Chemical (ATC) Classes for DESIPRAMINE HYDROCHLORIDE
US Patents and Regulatory Information for DESIPRAMINE HYDROCHLORIDE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alembic | DESIPRAMINE HYDROCHLORIDE | desipramine hydrochloride | TABLET;ORAL | 209785-006 | Jul 7, 2021 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Amneal Pharms Co | DESIPRAMINE HYDROCHLORIDE | desipramine hydrochloride | TABLET;ORAL | 208105-002 | Mar 17, 2016 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Chartwell Rx | DESIPRAMINE HYDROCHLORIDE | desipramine hydrochloride | TABLET;ORAL | 072103-003 | May 24, 1988 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for DESIPRAMINE HYDROCHLORIDE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Sanofi Aventis Us | PERTOFRANE | desipramine hydrochloride | CAPSULE;ORAL | 013621-002 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
Validus Pharms | NORPRAMIN | desipramine hydrochloride | TABLET;ORAL | 014399-004 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
Sanofi Aventis Us | PERTOFRANE | desipramine hydrochloride | CAPSULE;ORAL | 013621-001 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.